To directly evaluate the therapeutic potential of endotrophin neutralizing monoclonal antibodies on renal function and fibrotic parameters during chronic kidney diseases, control or POD-ATTAC mice subject to dimerizer induction (Day 0) were administered twice a week with intraperitoneal (i.p.)injections of either an isotype-adjusted IgG control or the monoclonal anti-mouse endotrophin antibody, clone ENT4-Mu. This evidence concerns the gene SLC29A4 and chronic kidney disease.